From 202d68a1599a8623e0fac30ae751d11157d26359 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 18:47:02 +0000 Subject: [PATCH] auto-fix: strip 4 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...model makes the net cost impact inflationary through 2035.md | 2 +- ...alue-across-kidney-cardiovascular-and-metabolic-endpoints.md | 2 +- ...abetic-obesity-patients-undermining-chronic-use-economics.md | 2 +- ...affordability-not-just-clinical-factors-drive-persistence.md | 2 +- 4 files changed, 4 insertions(+), 4 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index dc77a05c..64f46f58 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -97,7 +97,7 @@ If GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg ### Additional Evidence (challenge) -*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18* +*Source: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics | Added: 2026-03-18* Value in Health modeling study shows Medicare saves $715M over 10 years with comprehensive semaglutide access across all indications, challenging the universal inflationary framing. The distinction is payment structure: risk-bearing integrated payers can be net positive while fragmented systems remain inflationary. T2D savings ($892M) exceed obesity costs ($205M) when multi-indication benefits compound. diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index f889854e..f02739da 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -56,7 +56,7 @@ Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from a ### Additional Evidence (confirm) -*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18* +*Source: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics | Added: 2026-03-18* Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180 deaths prevented over 10 years. Per 100,000 subjects: 2,791 MIs, 3,000 revascularizations, 487 strokes, 115 CV deaths avoided. Savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. The multi-organ protection creates sufficient offset to produce net savings when a single payer captures all benefits. diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 778dc751..908bfeb4 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -79,7 +79,7 @@ WHO's conditional recommendation requiring behavioral therapy combination provid ### Additional Evidence (extend) -*Source: [[2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach]] | Added: 2026-03-18* +*Source: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach | Added: 2026-03-18* Weight regain data shows that even among patients who complete treatment, GLP-1 alone produces 8.7 kg regain (vs 7.6 kg placebo) while GLP-1 + exercise produces only 3.5 kg regain. This means low persistence may be economically rational for patients if the medication alone doesn't create lasting value—the 15% two-year persistence rate may reflect patients discovering that medication without lifestyle change produces temporary results. diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index 9ebba0b0..0c35f649 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -39,7 +39,7 @@ The source does not provide granular income-stratified discontinuation rates, so ### Additional Evidence (confirm) -*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* +*Source: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare | Added: 2026-03-16* The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.